Literature DB >> 28297057

Dialysis access: issues related to conversion from peritoneal dialysis to hemodialysis and vice versa.

Maurizio Gallieni1, Antonino Giordano1, Anna Ricchiuto1, Davide Gobatti2, Maurizio Cariati3.   

Abstract

ABSTRACTHemodialysis (HD) and peritoneal dialysis (PD) represent two complementary modalities of renal replacement therapy (RRT) for end-stage renal disease patients. Conversion between the two modalities is frequent and more likely to happen from PD to HD. Every year, 10% of PD patients convert to HD, suggesting the need for recommendations on how to proceed with the creation of a vascular access in these patients. Criteria for selecting patients who would likely fail PD, and therefore take advantage of a backup access, are undefined. Creating backup fistulas at the time of PD treatment start to allow emergency access for HD has proved to be inefficient, but it may be considered in patients with progressive difficulty in achieving adequate depuration and/or peritoneal ultrafiltration. A big challenge is represented by patients switching from PD to HD for unexpected infectious complications. Those patients need to start HD with a central venous catheter (CVC), but an alternative approach might be using an early cannulation graft, provided that infection has been cleared by the circulation. An early cannulation graft might also be used to considerably shorten the time spent using a CVC. In patients who need a conversion from HD to PD, urgent-start PD is now an accepted and well-established approach.

Entities:  

Mesh:

Year:  2017        PMID: 28297057     DOI: 10.5301/jva.5000695

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  1 in total

1.  Is combined peritoneal dialysis and hemodialysis redundant? A nationwide study from Taiwan.

Authors:  Mu-Chi Chung; Tung-Min Yu; Ming-Ju Wu; Ya-Wen Chuang; Chih-Hsin Muo; Cheng-Hsu Chen; Chao-Hsiang Chang; Jeng-Jer Shieh; Peir-Haur Hung; Jein-Wen Chen; Chi-Jung Chung
Journal:  BMC Nephrol       Date:  2020-08-15       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.